blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3840773

EP3840773 - TREATMENT OF HEPATITIS DELTA VIRUS INFECTION WITH INTERFERON LAMBDA [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  21.02.2025
Database last updated on 09.04.2026
FormerRequest for examination was made
Status updated on  28.05.2021
FormerThe international publication has been made
Status updated on  29.02.2020
Most recent event   Tooltip11.11.2025New entry: Decision on request for further processing 
Applicant(s)For all designated states
EIT Pharma, Inc.
11620 Wilshire Boulevard
Suite 350
Los Angeles, CA 90025 / US
[2025/11]
Former [2024/44]For all designated states
Eiger InnoTherapeutics, Inc.
2061 Webster Street
Palo Alto, CA 94301 / US
Former [2021/26]For all designated states
Eiger Biopharmaceuticals, Inc.
2155 Park Boulevard
Palo Alto, CA 94306 / US
Inventor(s)01 / CHOONG, Ingrid
2155 Park Boulevard
Palo Alto, California 94306 / US
02 / MARTINS, Eduardo Bruno
2155 Park Boulevard
Palo Alto, California 94306 / US
 [2021/26]
Representative(s)Patent Boutique LLP
10A Printing House Yard
Hackney Road
London E2 7PR / GB
[2021/26]
Application number, filing date19853099.023.08.2019
[2021/26]
WO2019US48038
Priority number, dateUS201862721763P23.08.2018         Original published format: US 201862721763 P
US201962823530P25.03.2019         Original published format: US 201962823530 P
US201962831548P09.04.2019         Original published format: US 201962831548 P
[2021/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020041778
Date:27.02.2020
Language:EN
[2020/09]
Type: A1 Application with search report 
No.:EP3840773
Date:30.06.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 27.02.2020 takes the place of the publication of the European patent application.
[2021/26]
Search report(s)International search report - published on:US27.02.2020
(Supplementary) European search report - dispatched on:EP25.04.2022
ClassificationIPC:A61K38/21, A61K47/60, A61P31/12
[2021/26]
CPC:
A61K45/06 (EP,IL); A61K38/21 (EP,IL,KR,US); A61K31/513 (KR);
A61K31/522 (EP,IL,KR,US); A61K31/675 (EP,IL,KR,US); A61K31/7072 (KR,US);
A61K47/60 (EP,IL,KR,US); A61K9/0021 (KR); A61P31/12 (EP,IL,KR);
A61P31/14 (US); G01N33/576 (US); G01N33/5765 (US);
A61K2300/00 (IL,KR) (-)
C-Set:
A61K31/522, A61K2300/00 (EP);
A61K31/675, A61K2300/00 (EP);
A61K38/21, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/26]
TitleGerman:BEHANDLUNG EINER HEPATITIS-DELTA-VIRUSINFEKTION MIT INTERFERON-LAMBDA[2021/26]
English:TREATMENT OF HEPATITIS DELTA VIRUS INFECTION WITH INTERFERON LAMBDA[2021/26]
French:TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE DELTA PAR L'INTERFÉRON LAMBDA[2021/26]
Entry into regional phase22.03.2021National basic fee paid 
22.03.2021Search fee paid 
22.03.2021Designation fee(s) paid 
22.03.2021Examination fee paid 
Examination procedure22.03.2021Examination requested  [2021/26]
27.02.2023Amendment by applicant (claims and/or description)
20.02.2025Despatch of a communication from the examining division (Time limit: M06)
04.09.2025Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
04.11.2025Reply to a communication from the examining division
Divisional application(s)EP22209211.6   Application refused  : 19.05.2023
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
04.11.2025Request for further processing filed
04.11.2025Full payment received (date of receipt of payment)
Request granted
10.11.2025Decision despatched
The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
27.02.2023Request for further processing filed
27.02.2023Full payment received (date of receipt of payment)
Request granted
10.03.2023Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
27.02.2023Request for further processing filed
27.02.2023Full payment received (date of receipt of payment)
Request granted
10.03.2023Decision despatched
Fees paidRenewal fee
26.10.2021Renewal fee patent year 03
18.07.2022Renewal fee patent year 04
05.07.2023Renewal fee patent year 05
11.07.2024Renewal fee patent year 06
03.07.2025Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.08.202103   M06   Fee paid on   26.10.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X] US2017042862  (CORY DAVID A et al.)
 [X]   HAMID SS ET AL: "A phase 2 randomised clinical trial to evaluate the safety and efficacy of pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 66, 1 January 2017 (2017-01-01), pages 496A, XP009516788, ISSN: 0270-9139
 [X]   ETZION OHAD ET AL: "End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection", JOURNAL OF HEPATOLOGY; INTERNATIONAL LIVER CONGRESS / 54TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-THE-LIVER (EASL); VIENNA, AUSTRIA; APRIL 10 -14, 2019, ELSEVIER, AMSTERDAM, NL, vol. 70, no. Suppl. 1, 31 March 2019 (2019-03-31), pages E32, XP009516780, ISSN: 0168-8278, Retrieved from the Internet DOI: 10.1016/S0618-8278(19)30058-1 [X] 1-4,8-15 * abstract *

DOI:   http://dx.doi.org/10.1016/S0618-8278(19)30058-1
 [XP]   ELAZAR MENASHE ET AL: "Emerging concepts for the treatment of hepatitis delta", CURRENT OPINION IN VIROLOGY, vol. 24, 1 June 2017 (2017-06-01), United Kingdom, pages 55 - 59, XP055912384, ISSN: 1879-6257, DOI: 10.1016/j.coviro.2017.04.004 [XP] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.coviro.2017.04.004
 [I]   GIERSCH KATJA ET AL: "Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice", SCIENTIFIC REPORTS, vol. 7, no. 1, 1 December 2017 (2017-12-01), XP055912353, Retrieved from the Internet DOI: 10.1038/s41598-017-03946-9 [I] 1-3 * page 58, column r *

DOI:   http://dx.doi.org/10.1038/s41598-017-03946-9
International search[XYA] WO2017143253  (EIGER BIOPHARMACEUTICALS INC et al.) [X] 1-5, 12, 13/5, 13/12, 14/5, 14/12, 15-18, 27/1, 27/3-4, 28/27/1, 28/27/3-4, 29/27/1, 29/27/3-4, 31/5, 31/12, 36-45, 62-68, 70-75, 80-81 * ; paragraphs [0009]-[0013], [0029], [0045], [0049], [0051]-[0052], [0054], [0057]-[0058], [0065]-[0067]; tables 1-2; claims 16-17, 19-20 *[Y] 46-47 [A] 6-11, 30, 32/31/5, 32/31/12, 48-61, 76-79
 [YA]   ANONYMOUS: "PEGASYS - Peg interferon alfa-2a", 1 January 2002 (2002-01-01), pages 1 - 47, XP055791184, Retrieved from the Internet [retrieved on 20191015] [Y] 46-47 * ; page 3, lines 97-99; page 7, line 226 - page 8, line 230; page 12, line 396; page 15, lines 502-505 *[A] 6-11, 32/31/5, 32/31/12, 48-61, 76-79
 [A]   ANONYMOUS: "A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients with Chronic Hepatitis Delta Virus Infection (LIMT)", 27 July 2018 (2018-07-27), pages 1 - 5, XP055791187, Retrieved from the Internet [retrieved on 20191015] [A] 6-11, 32/31/5, 32/31/12, 48-61, 76-79 * ; page 2/5, paragraph 1; page 3/5, paragraphs 1, 3 . *
 [A]   ANONYMOUS: "Novel Lambda Peg-Interferon Has Safety Edge Over Approved Peg- Interferon", 20 April 2012 (2012-04-20), pages 1 - 5, XP055791192, Retrieved from the Internet [retrieved on 20191015] [A] 30 * ; page 4/5, paragraph 2 *
 [A]   ANONYMOUS: "Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C", 3 February 2012 (2012-02-03), pages 1 - 6, XP055791196, Retrieved from the Internet [retrieved on 20191015] [A] 30 * ; page 2/7, box 13 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.